Oral All-D-Peptide Contraloid Advances to Human Safety Trial for Alzheimer's
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Summary
Contraloid (also called RD2 or PRI-002) is a novel oral drug made entirely of D-amino acids, engineered to break apart the toxic amyloid-beta oligomers believed to drive Alzheimer's disease. Unlike many Alzheimer's drugs that target amyloid plaques, Contraloid specifically targets the smaller, soluble oligomeric forms thought to be most neurotoxic. This Phase I multiple-ascending-dose trial enrolled 24 healthy volunteers to evaluate safety and tolerability across escalating doses. The drug had previously shown blood-brain barrier penetration and cognitive benefits in three separate transgenic mouse models across three independent laboratories. Human plasma levels matching those effective in mice had already been achieved in a prior single-dose study. This trial represents a critical early safety checkpoint before the drug can advance to Alzheimer's patients.
Detailed Summary
Alzheimer's disease remains one of the most devastating and treatment-resistant conditions in modern medicine. Despite decades of research and billions in investment, disease-modifying therapies have been elusive. Contraloid represents a mechanistically distinct approach: rather than clearing amyloid plaques after they form, it is designed to destroy the soluble amyloid-beta oligomers — sometimes described as prion-like replicating aggregates — that are increasingly implicated as the primary drivers of neuronal damage and cognitive decline.
This Phase I multiple-ascending-dose (MAD) trial enrolled 24 healthy adult volunteers at a single center in Germany, sponsored by Professor Dieter Willbold. The study was designed to evaluate the safety and tolerability of oral Contraloid across escalating dose levels, establishing the pharmacokinetic and safety profile needed to justify trials in Alzheimer's patients. The trial ran from December 2018 to April 2019 and has since been completed.
Contraloid is an all-D-peptide, meaning it is composed entirely of mirror-image amino acids. This unusual structural feature makes it highly resistant to proteolytic degradation in the gut and bloodstream, enabling effective oral bioavailability — a significant advantage over conventional peptide drugs. Preclinical data demonstrated blood-brain barrier penetration, direct target engagement with amyloid-beta oligomers, and cognitive improvements in three distinct transgenic Alzheimer's mouse models across three independent laboratories, even when treatment began after disease onset.
The implications are meaningful: if Contraloid proves safe and ultimately effective in humans, it could offer a truly oral, disease-modifying option for Alzheimer's — a disease with enormous unmet need. The drug's unique mechanism targeting oligomers rather than plaques also distinguishes it from antibody-based approaches like lecanemab.
However, Phase I trials are designed to assess safety, not efficacy. Results from this MAD study have not been published in full peer-reviewed form based on available information. Full safety and pharmacokinetic data are needed before efficacy conclusions can be drawn.
Key Findings
- Contraloid is an oral all-D-peptide that targets and disassembles toxic amyloid-beta oligomers implicated in Alzheimer's disease.
- The drug crosses the blood-brain barrier and showed cognitive benefits in three independent transgenic mouse models.
- Human plasma levels matching those effective in animal studies were achieved in a prior single-dose study.
- This MAD Phase I trial in 24 healthy volunteers was completed in April 2019, marking a key safety milestone.
- Oral bioavailability of an amyloid-targeting peptide would represent a major advance over current injectable biologics.
Methodology
This was a single-center, multiple-ascending-dose Phase I clinical trial enrolling 24 healthy adult volunteers to assess the safety and tolerability of escalating oral doses of Contraloid acetate. The trial was sponsored by Prof. Dr. Dieter Willbold and conducted in Germany between December 2018 and April 2019. No placebo-controlled efficacy outcomes were evaluated at this phase.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study results are not publicly available in open-access form. Phase I trials assess safety and tolerability, not efficacy, so no conclusions about cognitive or clinical benefit in Alzheimer's patients can be drawn. Full peer-reviewed publication of safety, tolerability, and pharmacokinetic results is needed to evaluate the drug's progress.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.